Market brief — July 30, 2026

Yesterday, markets closed in a clear risk-off repricing, with the CAC 40 at 8,408.27 (-0.6%), the S&P 500 at 7,316.15 (-1.52%), the Nasdaq at 24,442.94 (-1.74%), the DAX at 25,460.48 (-0.01%), and the Euro Stoxx 50 at 6,248.84 (-0.65%). The dominant driver was not a fresh growth scare but a higher-for-longer rates reset combined with late-month positioning pressure: equities sold off in the U.S. more aggressively than in Europe, which usually signals a mix of crowded long de-risking and CTA/systematic selling rather than a clean macro capitulation. The move matters because it came through the long-duration part of the market first, with the Nasdaq again leading downside, which keeps the burden on earnings to re-justify multiples over the next few sessions.

The cross-asset read-through is that the market is still trading as if bond yields can stay elevated without immediate policy relief, even if the exact catalyst is not a single headline. That tends to favor value, defensives and cash-generative balance sheets while pressuring high-duration growth and richly owned software/semiconductor exposure. The fact that the DAX was almost flat while U.S. indices sold off harder suggests Europe is still getting some support from lower positioning and more cyclically oriented earnings mix, but that divergence can narrow quickly if U.S. rate expectations tighten further or if the dollar resumes a bid. In this context, any upside in oil or a renewed move higher in Treasury real yields would likely extend the rotation away from long-duration assets; a reversal would require either softer growth data or a more dovish central-bank signal than the market currently expects.

Today’s Cash Scanner fits that rotation rather than contradicting it. The highest scores are concentrated in breakout-style moves across defensives, healthcare and idiosyncratic cyclical names: Envista Holding (NVST) scored 41 with a +5.2% gap and a 20-day breakout, Marsh & McLennan Companies (MMC) scored 40 with a +2.8% gap and ADX 29, and Takeda Pharmaceutical (TAK) scored 39 with a +1.3% gap and rising vortex/volume signals. There is also strength in Tetra Tech (TTEK) and Corteva (CTVA), both showing breakout or squeeze characteristics, while Life Time Group Holdings (LTH) and SiriusXM Holdings (SIRI) add a consumer/services and media overlay. The scanner is not screaming speculative risk-on; it points to selective accumulation in quality, defensive cash flows and a few beaten-down or technically compressing names, which is consistent with a market that is still selective and not broadly embracing beta. RTX’s (RTX) strong ADX reading despite a -1.5% gap is another reminder that defense remains bid even when the tape is choppy.

Over the next 1–5 sessions, the dominant narrative is whether this selloff becomes a durable rates-led de-risking or just a positioning flush before month-end rebalancing and earnings digestion. Consensus still appears to expect a soft landing with controlled disinflation, but that view is already partially priced in, especially in crowded growth and AI-linked areas. What is less certain is whether yields have already done enough damage to equities, or whether investors are underestimating the lag from tighter financial conditions into guidance and margins. A credible contrarian scenario is that the market stabilizes quickly if yields stop rising and defensives/healthcare continue to absorb flows, allowing the drawdown to remain contained rather than broadening into a full factor unwind.

The most important catalysts are the next batch of major U.S. mega-cap earnings, which will test whether profit growth can offset valuation pressure; any Treasury market move around supply and duration demand, which can quickly reprice equity duration; and the incoming inflation/growth data flow, which will shape the next Fed repricing. In Europe, any follow-through weakness in banks and cyclicals would tell you whether yesterday’s relative resilience was just a positioning artifact.

The main risks are a further upside surprise in yields, a disorderly extension of systematic selling into month-end, and earnings guidance that validates margin pressure rather than temporary volatility. If the S&P 500 holds above the 7,300 area while the Nasdaq stops underperforming and volatility eases, the current drawdown may be only a reset; if yields rise again and VIX stays sticky, the market likely has more de-risking to do. If Marsh & McLennan Companies, Takeda Pharmaceutical and Corteva keep outperforming while the Nasdaq lags, that would confirm the rotation into quality defensives; if RTX and Life Time Group Holdings roll over too, the defensive bid is fading as well.

Bonne journée aux p&l makers.